1. Genome-wide association study for residual concentrate intake using different approaches in Italian Brown Swiss. Issue 1 (1st January 2021) Authors: Manca, E.; Cesarani, A.; Falchi, L.; Atzori, A. S.; Gaspa, G.; Rossoni, A.; Macciotta, N. P. P.; Dimauro, C. Journal: Italian journal of animal science Issue: Volume 20:Issue 1(2021) Page Start: 1957 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. (23rd February 2016) Authors: Falchi, L.; Vitale, C.; Keating, M. J.; Lerner, S.; Wang, X.; Elhor Gbito, K. Y.; Strom, S.; Wierda, W. G.; Ferrajoli, A. Journal: Annals of oncology Issue: Volume 27:Number 6(2016:Jun.) Page Start: 1100 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE. (23rd June 2022) Authors: Belada, D.; Leppä, S.; Wahlin, B. E.; Nijland, M.; Christensen, J. H.; de Vos, S.; Holte, H.; Linton, K. M.; Abbas, A.; Wang, L.; Dinh, M.; Elliott, B.; Falchi, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1025 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE. (23rd June 2022) Authors: Clausen, M. R.; Offner, F.; Belada, D.; Brody, J.; Linton, K. M.; Karimi, Y.; Cordoba, R.; Snauwaert, S.; Abbas, A.; Wang, L.; Wu, J.; Elliott, B.; Falchi, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1100 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P1215: PRELIMINARY PHASE 1/2 RESULTS OF SUBCUTANEOUS EPCORITAMAB + R-DHAX/C IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT. (23rd June 2022) Authors: Cordoba, R.; Falchi, L.; Phillips, T.; de Vos, S.; Nijland, M.; Offner, F.; Bykhovski, I.; Wu, J.; Wang, L.; Rana, A.; Abrisqueta, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. TARGETING THE PERIPHERAL T‐CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5‐AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL‐MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY. (12th June 2019) Authors: Falchi, L.; Lue, J.K.; Montanari, F.; Marchi, E.; Amengual, J.E.; Sawas, A.; Deng, C.; Khan, K.; Kim, H.A.; Rada, A.; Malanga, M.; Francescone, M.F.; Soderquist, C.R.; Park, D.C.; Bhagat, G.; Sokol, L.; Shustov, A.R.; O'Connor, O.A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 178 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. THE COMBINATION OF DUVELISIB AND ROMIDEPSIN (DR) IS HIGHLY ACTIVE AGAINST RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA WITH LOW RATES OF TRANSAMINITIS: FINAL RESULTS. (17th June 2021) Authors: Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; Maccaro, C.; Blouin, W.; Schwieterman, J.; Cathcart, E.; Fang, S.; Perez, L.; Ryu, S.; Galasso, N.; Straus, D.; Fisher, D. C. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗